Novo Nordisk Retains 60% of List Price for Ozempic and Wegovy Novo Nordisk, the pharmaceutical company behind medications for diabetes and obesity, has revealed that it retains around sixty percent of the list price for its drugs, Ozempic and Wegovy, in the United States. These drugs have been widely used in the treatment of obesity…
